Background: The role of vascular endothelial growth factor (VEGF) rs3025039 polymorphism on osteosarcoma risk was not fully clear. Thus, we did a case-control study to evaluate the association between VEGF rs3025039 polymorphism and osteosarcoma risk.
Method: This study included 242 patients with osteosarcoma and 253 controls. The genotyping was conducted using the matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS).
Results: The VEGF rs3025039 TT genotype was significant higher in the osteosarcoma group than in the control group (OR=2.42, 95%CI 1.00-5.85, P=0.04). The TT genotype and CT genotype was also significantky associated with osteosarcoma risk (OR=1.43, 95%CI 1.00-2.05, P=0.04). Under the allelic model, T allele of rs3025039 was significantly associated with higher osteosarcoma risk (OR=1.41, 95%CI 1.05-1.90, P=0.02). In addition, VEGF rs3025039 TT genotype was not associated with tumor location (OR=1.02, 95%CI 0.59-1.77, P=0.94) and metastasis (OR=1.76, 95%CI 0.90-3.43, P=0.10).
Conclusion: In conclusion, this study confirmed that VEGF rs3025039 polymorphism was significantly associated with higher risk of osteosarcoma.Author(s): Jian Li, Tao Zhou, Hao Lin, Xiaoqiang Chen, Shaoqian Wang, Zongsheng Yin